# In vivo CAR-T manufactured and priced like a generic biologic

Source: https://onco.cc/ideas/idea-moon-in-vivo-cart-generic-price/  
OnCo record `idea-moon-in-vivo-cart-generic-price` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Instead of making cell therapy from each patient's own cells in a factory, inject a particle that reprograms immune cells inside the body, made in bulk, so a dose costs thousands rather than hundreds of thousands.

## Summary

Autologous CAR-T costs hundreds of thousands of dollars and weeks of manufacturing per patient, restricting it to a small fraction of eligible patients in rich countries. In vivo CAR generation with lipid nanoparticles or targeted lentiviral vectors (Umoja, Interius, Orna and others) has entered the clinic in B-cell malignancies. The proposal is a coordinated programme to develop an in vivo CD19 or BCMA product with a manufacturing process and cost-of-goods target under $5,000 per dose, licensed for distribution through generic-style manufacturers in middle-income countries, with regulatory pathways agreed in advance.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: An off-the-shelf in vivo CAR product achieves complete remission rates within 15 percentage points of autologous CAR-T in relapsed B-cell malignancies at less than a tenth of the delivered cost, enabling treatment of ten times as many patients.
- Rationale: The cost of autologous therapy is in logistics and bespoke manufacturing, not in the biology; nucleic acid-lipid manufacturing scales like a vaccine.
- Proposed test: Phase 2 in relapsed large B-cell lymphoma with pre-specified cost-of-goods reporting and a parallel technology transfer to a manufacturer in India or Brazil.
- Maturity: preclinical-evidence
- Actor: industry

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- ideas: [In vivo CAR-T against solid-tumour antigens](https://onco.cc/ideas/idea-in-vivo-car-solid/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- companies: [Interius BioTherapeutics](https://onco.cc/companies/interius/), [Orna Therapeutics (Eli Lilly)](https://onco.cc/companies/orna-therapeutics/), [Umoja Biopharma](https://onco.cc/companies/umoja-biopharma/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial](https://onco.cc/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/), [B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches](https://onco.cc/key-papers/paper-bcma-multiple-myeloma-leukemia-2020/), [How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies](https://onco.cc/key-papers/paper-cd19-multiple-myeloma-blood-2020/), [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-in-vivo-cart-generic-price.json